Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase-mediated mTOR activation in tuberous sclerosis and human cancer

Cancer Research

Volumn 67, Issue 15, 2007, Pages 7106-7112

  Ma, Li ^a,b,d   Teruya Feldstein, Julie ^a   Bonner, Pauline ^a   Bernardi, Rosa ^a   Franz, David Neal ^c   Witte, David ^c   Cordon Cardo, Carlos ^a   Pandolfi, Pier Paolo ^a,e  

^a Department of Obstetrics Gynecology   (United States)

^b Weill Cornell Graduate School of Biomedical Sciences   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN S6; TUBERIN;

ARTICLE; ASTROCYTOMA CELL; BRAIN DAMAGE; BREAST CARCINOMA; CANCER; CARCINOGENESIS; COLON CARCINOMA; CORRELATION ANALYSIS; EMBRYO; ENZYME ACTIVATION; EPENDYMA CELL; FEMALE; GIANT CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INCIDENCE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SUBVENTRICULAR ZONE; TISSUE MICROARRAY; TUBEROUS SCLEROSIS;

CELLS, CULTURED; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; KIDNEY; MAP KINASE SIGNALING SYSTEM; NEOPLASMS; PHOSPHORYLATION; PROTEIN KINASES; SERINE; TISSUE ARRAY ANALYSIS; TRANSFECTION; TUBEROUS SCLEROSIS; TUMOR SUPPRESSOR PROTEINS;

EID: 34547645033     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-4798     Document Type: Article

References (20)

1. Lewis TS, Shapiro PS, Ahn NG. Signal transduction through MAP kinase cascades. Adv Cancer Res 1998;74:49-139.
2. Hoshino R, Chatani Y, Yamori T, et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 1999;18:813-22.
3. Oka H, Chatani Y, Hoshino R, et al. Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res 1995;55:4182-7.
4. Adeyinka A, Nui Y, Cherlet T, Snell L, Watson PH, Murphy LC. Activated mitogen-activated protein kinase expression during human breast tumorigenesis and breast cancer progression. Clin Cancer Res 2002;8:1747-53.
5. Milde-Langosch K, Bamberger AM, Rieck G, et al. Expression and prognostic relevance of activated extracellular-regulated kinases (ERK1/2) in breast cancer. Br J Cancer 2005;92:2206-15.
6. Givant-Horwitz V, Davidson B, Lazarovici P, et al. Mitogen-activated protein kinases (MAPK) as predictors of clinical outcome in serous ovarian carcinoma in effusions. Gynecol Oncol 2003;91:160-72.
7. Vicent S, Lopez-Picazo JM, Toledo G, et al. ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours. Br J Cancer 2004;90:1047-52.
8. Sebolt-Leopold JS, Dudley DT, Herrera R, et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 1999;5:810-6.
9. Govindarajan B, Mizesko MC, Miller MS, et al. Tuberous sclerosis-associated neoplasms express activated p42/44 mitogen-activated protein (MAP) kinase, and inhibition of MAP kinase signaling results in decreased in vivo tumor growth. Clin Cancer Res 2003;9:3469-75.
10. Han S, Santos TM, Puga A, et al. Phosphorylation of tuberin as a novel mechanism for somatic inactivation of the tuberous sclerosis complex proteins in brain lesions. Cancer Res 2004;64:812-6.
11. Niida Y, Stemmer-Rachamimov AO, Logrip M, et al. Survey of somatic mutations in tuberous sclerosis complex (TSC) hamartomas suggests different genetic mechanisms for pathogenesis of TSC lesions. Am J Hum Genet 2001;69:493-503.
12. Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 2005;121:179-93.
13. Hedvat CV, Hegde A, Chaganti RS, et al. Application of tissue microarray technology to the study of non-Hodgkin's and Hodgkin's lymphoma. Hum Pathol 2002;33:968-74.
14. Curatolo P, Verdecchia M, Bombardieri R. Tuberous sclerosis complex: a review of neurological aspects. Eur J Paediatr Neurol 2002;6:15-23.
15. Gomez MR. Tuberous sclerosis. 2nd ed. New York: Raven Press; 1988.
16. Henske EP, Scheithauer BW, Short MP, et al. Allelic loss is frequent in tuberous sclerosis kidney lesions but rare in brain lesions. Am J Hum Genet 1996;59:400-6.
17. Franz DN, Leonard J, Tudor C, et al. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 2006;59:490-8.
18. Thomas GV, Horvath S, Smith BL, et al. Antibodybased profiling of the phosphoinositide 3-kinase pathway in clinical prostate cancer. Clin Cancer Res 2004;10:8351-6.
19. Horiguchi A, Oya M, Uchida A, Marumo K, Murai M. Elevated Akt activation and its impact on clinicopathological features of renal cell carcinoma. J Urol 2003;169:710-3.
20. Roy HK, Olusola BF, Clemens DL, et al. AKT protooncogene overexpression is an early event during sporadic colon carcinogenesis. Carcinogenesis 2002;23:201-5.